Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Growth in Short Interest

Aditxt, Inc. (NASDAQ:ADTX) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,000 shares, an increase of 150.0% from the October 15th total of 400 shares. Based on an average daily trading volume, of 227,900 shares, the short-interest ratio is currently 0.0 days. Approximately 0.5% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their target price on shares of Aditxt to $61.00 and gave the stock a “buy” rating in a research report on Wednesday, September 6th.

Insider Buying and Selling

In other Aditxt news, major shareholder Paribas Securities Corp Bnp sold 20,800 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $33.23, for a total value of $691,184.00. Following the completion of the transaction, the insider now directly owns 22,342 shares of the company’s stock, valued at approximately $742,424.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.23% of the stock is owned by insiders.

Institutional Trading of Aditxt

A hedge fund recently bought a new stake in Aditxt stock. Bank of New York Mellon Corp acquired a new position in Aditxt, Inc. (NASDAQ:ADTX) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 34,968 shares of the company’s stock, valued at approximately $119,000. Bank of New York Mellon Corp owned 2.99% of Aditxt at the end of the most recent reporting period.

Aditxt Trading Down 4.3 %

Aditxt stock opened at $4.17 on Friday. The firm has a 50-day moving average of $13.95 and a 200-day moving average of $22.44. Aditxt has a 1-year low of $4.08 and a 1-year high of $78.40.

Aditxt (NASDAQ:ADTX) last posted its earnings results on Monday, August 14th. The company reported ($36.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($115.60) by $78.80. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.36 million. Aditxt had a negative net margin of 2,891.14% and a negative return on equity of 777.58%. On average, analysts expect that Aditxt will post -235.2 earnings per share for the current year.

About Aditxt

Aditxt, Inc, a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.